45
Participants
Start Date
April 1, 2024
Primary Completion Date
April 29, 2028
Study Completion Date
August 1, 2029
ChAdOx1.tHIVconsv1
Administered as 0.4 mL intramuscularly (IM) at Week 0
ChAdOx1.HIVconsv62
Administered as 0.3 mL IM at Week 0
MVA.tHIVconsv3
Administered as 0.3 mL IM at Week 4
MVA.tHIVconsv4
Administered as 0.5 mL IM at week 4
Vesatolimod (VES)
VES 6 mg administered orally once every 2 weeks for two doses, then VES 8 mg once every 2 weeks for 8 doses. Dose escalation may be held or the 8 mg dose may be reduced for intolerability for weeks 6 through 24.
GS-5423
Administered via intravenous (IV) infusion at week 7
GS-2872
Administered via IV infusion at week 7
MVA.tHIVconsv4
Administered 0.5 mL IM at week 60
Placebo
Placebos for vaccines, VES, and bnAbs
RECRUITING
Columbia Physicians & Surgeons CRS, New York
RECRUITING
Penn Therapeutics CRS, Philadelphia
NOT_YET_RECRUITING
Greensboro CRS, Greensboro
RECRUITING
Chapel Hill CRS, Chapel Hill
RECRUITING
Ponce de Leon Center CRS, Atlanta
RECRUITING
Ohio State University CRS, Columbus
NOT_YET_RECRUITING
Cincinnati CRS, Cincinnati
RECRUITING
Northwestern University CRS, Chicago
RECRUITING
Washington University Therapeutics CRS, St Louis
RECRUITING
Houston AIDS Research Team CRS, Houston
RECRUITING
University of California, San Diego AntiViral Research Center CRS, San Diego
NOT_YET_RECRUITING
Massachusetts General Hospital CRS (MGH CRS), Boston
RECRUITING
Instituto de Pesquisas em AIDS do Rio Grande do Sul - IPARGS CRS, Porto Alegre
NOT_YET_RECRUITING
Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS, Rio de Janeiro
Collaborators (1)
University of Oxford
OTHER
Gilead Sciences
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH